A new analgesic agent based on hexaazaisowurzitan: feasibility of using in managing patients with cancer

Purpose: to study gastrotoxic and ulcerogenic effects of a long-term administration of a newly synthesized compound from the hexaazaisowurzitan (thiowurtzine) series in rats, as well as to assess its effect on the transplantable tumor in mice.Material and Methods. Lewis lung carcinoma was transplant...

Full description

Saved in:
Bibliographic Details
Main Authors: K. A. Lopatina, S. G. Krylova, E. A. Safonova, E. P. Zueva, D. A. Kulagina, А. A. Churin, T. I. Fomina, S. V. Sysolyatin
Format: Article
Language:Russian
Published: Russian Academy of Sciences, Tomsk National Research Medical Center 2020-04-01
Series:Сибирский онкологический журнал
Subjects:
Online Access:https://www.siboncoj.ru/jour/article/view/1402
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849408321891598336
author K. A. Lopatina
S. G. Krylova
E. A. Safonova
E. P. Zueva
D. A. Kulagina
А. A. Churin
T. I. Fomina
S. V. Sysolyatin
author_facet K. A. Lopatina
S. G. Krylova
E. A. Safonova
E. P. Zueva
D. A. Kulagina
А. A. Churin
T. I. Fomina
S. V. Sysolyatin
author_sort K. A. Lopatina
collection DOAJ
description Purpose: to study gastrotoxic and ulcerogenic effects of a long-term administration of a newly synthesized compound from the hexaazaisowurzitan (thiowurtzine) series in rats, as well as to assess its effect on the transplantable tumor in mice.Material and Methods. Lewis lung carcinoma was transplanted into mice, and thiowurtzine was prescribed for a long course together with cyclophosphamide. In the terminal stage of tumor development the mass of the primary node, the number and area of metastases in the lungs of mice were measured. Histological sections of the stomach were studied in rats after a 90-day administration of thiowurtzine.Results. Thiowurtzine at therapeutic dosages of 50 and 100 mg/kg for a course of 19 days potentiated the effect of cyclophosphamide to inhibit tumor dissemination and exerted a direct antitumor effect in mice with lewis lung carcinoma. A dose of 1000 mg/kg for 90 days did not cause ulcerogenic action of thiowurtzine.Conclusion. The absence of a stimulating effect on tumor growth in animal experiments and intactness in relation to the gastric mucosa during chronic administration of thiowurtzine allow us to recommend this innovative analgesic for clinical study as a concomitant analgesia in cancer patients.
format Article
id doaj-art-e0ed02ed56234b63a6fdfa11e2c54182
institution Kabale University
issn 1814-4861
2312-3168
language Russian
publishDate 2020-04-01
publisher Russian Academy of Sciences, Tomsk National Research Medical Center
record_format Article
series Сибирский онкологический журнал
spelling doaj-art-e0ed02ed56234b63a6fdfa11e2c541822025-08-20T03:35:48ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682020-04-01192768110.21294/1814-4861-2020-19-2-76-81731A new analgesic agent based on hexaazaisowurzitan: feasibility of using in managing patients with cancerK. A. Lopatina0S. G. Krylova1E. A. Safonova2E. P. Zueva3D. A. Kulagina4А. A. Churin5T. I. Fomina6S. V. Sysolyatin7Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of SciencesGoldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of SciencesGoldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of SciencesGoldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of SciencesInstitute for Problems of Chemical and Energetic Technologies of the Siberian Branch оf the Russian Academy of SciencesGoldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of SciencesGoldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of SciencesInstitute for Problems of Chemical and Energetic Technologies of the Siberian Branch оf the Russian Academy of SciencesPurpose: to study gastrotoxic and ulcerogenic effects of a long-term administration of a newly synthesized compound from the hexaazaisowurzitan (thiowurtzine) series in rats, as well as to assess its effect on the transplantable tumor in mice.Material and Methods. Lewis lung carcinoma was transplanted into mice, and thiowurtzine was prescribed for a long course together with cyclophosphamide. In the terminal stage of tumor development the mass of the primary node, the number and area of metastases in the lungs of mice were measured. Histological sections of the stomach were studied in rats after a 90-day administration of thiowurtzine.Results. Thiowurtzine at therapeutic dosages of 50 and 100 mg/kg for a course of 19 days potentiated the effect of cyclophosphamide to inhibit tumor dissemination and exerted a direct antitumor effect in mice with lewis lung carcinoma. A dose of 1000 mg/kg for 90 days did not cause ulcerogenic action of thiowurtzine.Conclusion. The absence of a stimulating effect on tumor growth in animal experiments and intactness in relation to the gastric mucosa during chronic administration of thiowurtzine allow us to recommend this innovative analgesic for clinical study as a concomitant analgesia in cancer patients.https://www.siboncoj.ru/jour/article/view/1402analgesiatumorthiowurtzinehexaazaisowurzitanlewis lung carcinoma
spellingShingle K. A. Lopatina
S. G. Krylova
E. A. Safonova
E. P. Zueva
D. A. Kulagina
А. A. Churin
T. I. Fomina
S. V. Sysolyatin
A new analgesic agent based on hexaazaisowurzitan: feasibility of using in managing patients with cancer
Сибирский онкологический журнал
analgesia
tumor
thiowurtzine
hexaazaisowurzitan
lewis lung carcinoma
title A new analgesic agent based on hexaazaisowurzitan: feasibility of using in managing patients with cancer
title_full A new analgesic agent based on hexaazaisowurzitan: feasibility of using in managing patients with cancer
title_fullStr A new analgesic agent based on hexaazaisowurzitan: feasibility of using in managing patients with cancer
title_full_unstemmed A new analgesic agent based on hexaazaisowurzitan: feasibility of using in managing patients with cancer
title_short A new analgesic agent based on hexaazaisowurzitan: feasibility of using in managing patients with cancer
title_sort new analgesic agent based on hexaazaisowurzitan feasibility of using in managing patients with cancer
topic analgesia
tumor
thiowurtzine
hexaazaisowurzitan
lewis lung carcinoma
url https://www.siboncoj.ru/jour/article/view/1402
work_keys_str_mv AT kalopatina anewanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer
AT sgkrylova anewanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer
AT easafonova anewanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer
AT epzueva anewanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer
AT dakulagina anewanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer
AT aachurin anewanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer
AT tifomina anewanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer
AT svsysolyatin anewanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer
AT kalopatina newanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer
AT sgkrylova newanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer
AT easafonova newanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer
AT epzueva newanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer
AT dakulagina newanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer
AT aachurin newanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer
AT tifomina newanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer
AT svsysolyatin newanalgesicagentbasedonhexaazaisowurzitanfeasibilityofusinginmanagingpatientswithcancer